Agile Therapeutics Inc expected to post a loss of 44 cents a share - Earnings Preview

Agile Therapeutics

05/11/2022 03:05

* Agile Therapeutics Inc  AGRX.OQ   AGRX.O  is expected
to show a
rise in quarterly revenue when it reports  results on November
7. 
    * The Princeton New Jersey-based  company is expected to
report  a
81.3% increase in revenue to $2.334 million from $1.29 million a
year ago, according to the mean estimate from 2 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Agile Therapeutics
Inc is
for a loss of 44 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Agile
Therapeutics Inc is $3​, above​ its last closing price of $0.27.
​​​

This summary was machine generated November 5 at 03:04 GMT.  All
figures in US dollars  unless otherwise stated